AURA — Aura Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1501796 ·
Last close
$7.15
Market Cap
$744.13M
52W High
$9.53
52W Low
$4.73
ADV30
850,440
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -35,062,000 | -32,066,000 | 321,617,000 | 41,669,000 | 34,190,000 |
| Jun 2026 | 0 | — | -48,069,000 | -45,637,000 | 348,129,000 | 67,836,000 | 32,862,000 |
| Mar 2026 | 0 | — | -34,866,000 | -33,685,000 | 137,677,000 | 84,793,000 | 30,430,000 |
| Dec 2025 | 0 | — | -27,237,000 | -25,559,000 | 169,430,000 | 59,515,000 | 32,517,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-109,303,000
Investing CF
$-141,199,000
Financing CF
$245,025,000
CapEx
$-379,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.67
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-591,806,000
Inventory
—
Receivables
$1,871,000
ST Investments
$255,564,000
EBIT TTM
$-145,234,000
Pretax Income TTM
$-136,854,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -112,791,000 | -106,191,000 | 169,430,000 | 32,517,000 | 136,913,000 | -84,742,000 |
| Dec 2024 | 0 | -96,116,000 | -86,919,000 | 182,503,000 | 30,533,000 | 151,970,000 | -79,805,000 |
| Dec 2023 | 0 | -84,991,000 | -76,408,000 | 255,075,000 | 29,227,000 | 225,848,000 | -63,847,000 |
| Dec 2022 | 0 | -60,295,000 | -58,763,000 | 223,935,000 | 28,352,000 | 195,583,000 | -54,601,000 |
TTM Snapshot
Revenues TTM
$153,817,000
NetIncome TTM
$-131,011,000
OpCashFlow TTM
—
Assets (Latest)
$348,129,000
Forward EPS
$-2.03
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $7.14 · call volume: 13 · put volume: 1Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GLUE | Monte Rosa Therapeutics, Inc. | $775.03M | $9.07 | — |
| SLDB | Solid Biosciences Inc. | $695.33M | $6.23 | — |
| ATTO | Attovia Therapeutics, Inc. | $679.29M | $14.86 | — |
| IAM | Iambic Therapeutics, Inc. | $674.04M | $14.22 | — |
| MGTX | MeiraGTx Holdings plc | $826.80M | $8.46 | — |
News headlines (Yahoo Finance, 1h cache)
OXB confirms partnership with Aura Biosciences supporting Phase 3 development and future commercial supply of lead oncology candidate
2026-11-17 12:00 · Yahoo
Wall Street Analysts Believe Aura Biosciences (AURA) Could Rally 119.61%: Here's is How to Trade
2026-11-11 20:19 · Yahoo
Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-09 12:00 · Yahoo
Aura Biosciences to Participate in Upcoming Investor Conference
2026-11-03 21:02 · Yahoo
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 20:28 · Yahoo
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-11 11:00 · Yahoo
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-05-04 10:03 · Yahoo
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-11 20:01 · Yahoo
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-05-05 21:15 · Yahoo
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
2026-05-04 13:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.